Total pharmaceutical sales in Finland during February–April 2009 were EUR 493 (481) million in PPP, which represents growth of 3% compared to the same period in the previous year.
Tamro Finland’s net sales in February–April were EUR 279 (259) million, an increase of 7.6%. Tamro Finland’s average market share for February–April was 53%. The company employed an average of 327 (324) people.
The new medicine reference pricing model came into effect on 1 April 2009 causing uncertainty in the market. The new system is logistically challenging for all market actors – pharmacies, pharmaceutical companies, authorities and wholesalers – as the demand for individual products can fluctuate significantly in a short period of time. However, Tamro Finland’s service level was successfully kept on an acceptable level in April, thus ensuring medicine availability for patients.
The reference price model will reduce market growth; the full-year market growth is estimated to be around 1–2%.
